- Lilly Canada’s Ebglyss (lebrikizumab) received a positive CDA-AMC reimbursement recommendation, while a pCPA Letter of Intent clears the path for broader public drug coverage across Canada.
- Ebglyss is indicated for moderate-to-severe atopic dermatitis (eczema) and is already reimbursed in Quebec through RAMQ following a positive INESSS recommendation.
- The recommendation is backed by the ADvocate 1, ADvocate 2, and ADhere studies, showing significant skin clearance, itch relief, and improved quality of life, with benefits maintained for up to four years.
- Lilly will now work with provincial drug plans to expand patient access, offering another biologic treatment option for Canadians living with moderate-to-severe eczema.
Takeaways
Ebglyss is now positioned to move from province‑specific coverage into broad, pan-Canadian reimbursement, which should materially expand Lilly’s eczema market and patient access. This unlocks a much larger pool of moderate‑to‑severe atopic dermatitis patients beyond Quebec’s RAMQ, supported by long‑term ADvocate/ADhere data showing durable skin clearance and itch relief for up to four years, and gives dermatologists another reimbursed biologic option alongside existing IL‑4/13 and JAK therapies.
Source: CA Newswire
